Gilead Sciences’ Sunlenca Receives NMPA Approval for Multidrug-Resistant HIV-1 Infection
US-based pharmaceutical company Gilead Sciences Inc., (NASDAQ: GILD), has announced that it has received marketing...
WinHealth Pharma’s Difelikefalin Receives NMPA Review for Market Approval
China-based Hong Kong WinHealth Pharma Group has announced that the National Medical Products Administration (NMPA)...
Shanghai Enacts New Regulations for Drug and Medical Device Administration
The Standing Committee of the Shanghai Municipal People’s Congress has approved and released the “Regulations...
Thederma’s TAN-118 Receives Tacit Clinical Approval from China’s CDE for Global Trials
Shanghai-based Thederma has announced that its drug candidate TAN-118 has obtained tacit clinical approval from...
Shenzhen Hepalink Pharmaceuticals to Distribute Gabapentin in US under New Agreement
China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399, HKG: 9989) has announced a product...
Innovent Biologics’ Taletrectinib Gains NMPA Approval for ROS1 Positive NSCLC
China-based Innovent Biologics, Inc. (HKG: 1801) has announced receiving an additional marketing approval from the...
MabPharm’s CMAB807 Biosimilar Infliximab Approved in Pakistan
Taizhou-based monoclonal antibody (mAb) biosimilar specialist MabPharm Ltd (HKG: 2181) has announced the receipt of...
Zhaoke Ophthalmology’s NVK002 ANDA Accepted for Review by China’s NMPA
China-based Lee’s Pharmaceutical Holdings Ltd’s (HKG: 0950) former subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has...
Grand Pharmaceutical Initiates Study on GPN00289 for Liver Cancer Treatment
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced the first patient enrollment in...
SCG Cell Therapy’s SCG142 Receives NMPA Approval for HPV-Related Solid Tumor Clinical Trial
SCG Cell Therapy Pte. Ltd, a Singapore-based company with a presence in Shanghai, has received...
Huadong Medicine’s HDM1005 Receives NMPA Approval for MAFLD/MASH Clinical Trial
Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received clinical trial approval...
Cygenta Partners with IZVARINO Pharma for Comprehensive CDMO Services
Cygenta, a cell and gene therapy (CGT) focused Contract Development and Manufacturing Organization (CDMO) based...
Pfizer Collaborates with Atavistik Bio to Discover Allosteric Therapeutics
US pharmaceutical giant Pfizer (NYSE: PFE) has entered into a research collaboration with compatriot firm...
NMPA Grants Conditional Approval for China’s First MSCs Therapy for aGVHD
The National Medical Products Administration (NMPA) in China has conditionally approved amimestrocel from Beijing-based Platinum...
Genesis MedTech’s iReach Omnia Receives NMPA Approval for Rectal Cancer Surgery
Singapore-based medical device company Genesis MedTech has announced that it has received marketing approval from...
Eli Lilly & Co. Launches Mounjaro (Tirzepatide) in China for Diabetes and Weight Management
US pharmaceutical major Eli Lilly & Co. (NYSE: LLY) has announced the official market launch...
Prime Gene Therapeutics Secures Over RMB300 Million in Series B Financing
Beijing-based Prime Gene Therapeutics Co., Ltd (873969.NQ), a clinical-stage biotech company specializing in immune inflammatory...
Brii Biosciences to Acquire Full Rights to BRII-179 from VBI Vaccines
China-based Brii Biosciences Ltd (HKG: 2137) has announced its intention to acquire the intellectual property...
Shanghai Pharmaceuticals Halts Development of I001-B, I022, and C012 in the US
China’s Shanghai Pharmaceuticals (SPH, HKG: 2607, SHA: 601607) has declared the termination of clinical trials...
Astellas Pharma’s Vyloy Approved by NMPA for CLDN18.2 Positive Gastric Cancer
China’s National Medical Products Administration (NMPA) has indicated on its website that Japan-based Astellas Pharma...